Ribociclib Added to Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Demonstrated Favorable Quality-of-Life Results
Examining Different Sequence Effects of CDK4/6 Inhibitor Combinations on Actual Real-World Outcomes of Treatment in Patients with Hormone Receptor–Positive and HER2-Negative Metastatic Breast Cancer
Comparison of Healthcare Resource Utilization and Costs in Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
In this real-world setting study, similar healthcare costs and healthcare resource utilization among patients treated with ribociclib and palbociclib were observed. However, fewer inpatient days were experienced by patients treated with ribociclib when compared with abemaciclib.
Incidence of Thrombotic Events with CDK4/6 Inhibitor Use in Real-World Practice Compared with Clinical Trial Settings
Assessment of Characteristics, Utilization Patterns, and Outcomes in the Real-World Setting of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer Treated with Abemaciclib
Capecitabine or Endocrine Therapy as Maintenance Therapy for Hormone Receptor–Positive, HER2-Negative Breast Cancer
Primary analysis of a multicenter, randomized clinical trial suggests that endocrine therapy demonstrates benefits over capecitabine when used as a maintenance therapy after first-line combination chemotherapy in hormone receptor–positive, HER2-negative advanced metastatic breast cancer.
Real-World Data of Palbociclib and Endocrine Therapy in Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
This real-world study of patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with a palbociclib-based therapy as either first- or second-line therapy, showed similar safety and efficacy when compared with clinical study results.
Impact of the COVID-19 Pandemic in the United States on First-Line Treatment Trends in Metastatic Breast Cancer
During the COVID-19 pandemic, there was a decline in the number of patients beginning first-line treatment. There was a decrease in the percentage of patients receiving CDK4/6 inhibitor combination therapy while a simultaneous increase in endocrine monotherapy was observed.
Updated Results from the Phase 3b CompLEEment-1 Study of Ribociclib plus Letrozole in the Treatment of Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In a large, diverse cohort of patients, this analysis confirms the safety and efficacy of ribociclib plus letrozole with data that are consistent with those observed in the MONALEESA trials, supporting the use of this combination in the first-line setting.
For Patients with PIK3CA Mutation–Positive Advanced Breast Cancer, Treatment with Alpelisib plus Fulvestrant May Be Beneficial
When combined with fulvestrant, alpelisib produced clinically and statistically relevant progression-free survival despite the baseline poorer prognosis in patients with hormone receptor–positive, HER2-negative, PIK3CA mutation–positive advanced breast cancer.
Page 2 of 12
Results 11 - 20 of 118
Results 11 - 20 of 118